Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Sho Isoyama"'
Autor:
Xin Peng, Xin Huang, Talal Ben Lulu, Wenqing Jia, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Xi Chen, Shanshan Liu, Yongzhe Wang, Kailin Wang, Sho Isoyama, Shingo Dan, Feng Wang, Zhe Zhang, Moshe Elkabets, Dexin Kong
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-23 (2024)
Abstract Background Phosphoinositide 3-kinases (PI3Ks) are critical regulators of diverse cellular functions and have emerged as promising targets in cancer therapy. Despite significant progress, existing PI3K inhibitors encounter various challenges
Externí odkaz:
https://doaj.org/article/8ff42a862e624392b12fa5dce4b9e982
Autor:
Kazuma Takeuchi, Yumiko Nishimura, Takayoshi Matsubara, Sho Isoyama, Asuka Suzuki, Masaaki Matsuura, Shingo Dan
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 3, Pp n/a-n/a (2024)
Abstract Interference in cell cycle progression has been noted as one of the important properties of anticancer drugs. In this study, we developed the cell cycle prediction model using high‐content imaging data of recipient cells after drug exposur
Externí odkaz:
https://doaj.org/article/946b9981c185449d964dbaa9a8975171
Autor:
Sho Isoyama, Naomi Tamaki, Yutaka Noguchi, Mutsumi Okamura, Yuki Yoshimatsu, Tadashi Kondo, Takeshi Suzuki, Shin-ichi Yaguchi, Shingo Dan
Publikováno v:
Cell Death and Disease, Vol 14, Iss 2, Pp 1-10 (2023)
Abstract Translocation-related sarcomas (TRSs) harbor an oncogenic fusion gene generated by chromosome translocation and account for approximately one-third of all sarcomas; however, effective targeted therapies have yet to be established. We previou
Externí odkaz:
https://doaj.org/article/449aec3bd3674ec2a73c663ca55309a8
Autor:
Kohei Shitara, Yasuko Tada, Hiroyoshi Nishikawa, Daisuke Sugiyama, Sho Isoyama, Shigeyuki Mori, Yasuhiro Kojima, Kunihiko Hinohara, Shingo Dan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/060063cff850479a9b08d3515c6c68c4
Autor:
Shingo Dan, Shigeyuki Mori, Yasuhiro Kojima, Kohei Shitara, Kunihiko Hinohara, Daisuke Sugiyama, Yasuko Tada, Hiroyoshi Nishikawa, Sho Isoyama
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
BackgroundImmune checkpoint blockade (ICB) induces durable clinical responses in patients with various types of cancer. However, its limited clinical efficacy requires the development of better approaches. In addition to immune checkpoint molecules,
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
The hatcing enzyme gene (HE) encodes a protease that is indispensable for the hatching process and is conserved during vertebrate evolution. During teleostean evolution, it is known that HE experienced a drastic transfiguration of gene structure, nam
Autor:
Naoki Nakamura, Hisashi Yoshimi, Gensei Kajiwara, Mutsumi Okamura, Kento Kawamura, Yumiko Nishimura, Naomi Tamaki, Shingo Dan, Nachi Namatame, Takao Yamori, Sho Isoyama
Publikováno v:
Cancer Science
Drug resistance often critically limits the efficacy of molecular targeted drugs. Although pharmacological inhibition of phosphatidylinositol 3-kinase (PI3K) is an attractive therapeutic strategy for cancer therapy, molecular determinants for efficac
Publikováno v:
Cancer Research. 78:4718-4718
The phosphoinositide 3-kinases (PI3Ks) transduce important signals involved in T-cell development and activation. Inhibition of the PI3Kδ isoform reportedly decreases regulatory T (Treg) cells and activates anti-tumor immunity in preclinical murine
Autor:
Tatsuro Irimura, Yumiko Nishimura, Shingo Dan, Takao Yamori, Naoki Nakamura, Mariko Seki, Sho Isoyama, Gensei Kajiwara
Publikováno v:
Cancer Sci
Acquired resistance is a major obstacle for conventional cancer chemotherapy, and also for some of the targeted therapies approved to date. Long‐term treatment using protein tyrosine kinase inhibitors (TKIs), such as gefitinib and imatinib, gives r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb543b59629f7be3d20792d8cabc522
https://europepmc.org/articles/PMC7659208/
https://europepmc.org/articles/PMC7659208/
Autor:
Takao Yamori, Mariko Seki, Shingo Dan, Tatsuro Irimura, Mutsumi Okamura, Hisashi Yoshimi, Sho Isoyama
Publikováno v:
Biologicalpharmaceutical bulletin. 35(9)
The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in human cancers by gain-of-function mutations of phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) or dysfunction of phosphatase and tensin homolog deleted on ch